BioMarin Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Alexander Hardy
Chief executive officer
US$18.6m
Total compensation
| CEO salary percentage | 0.3% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.7yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01
BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin: A Good Anchor For Your Biotech Portfolio
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | US$19m | US$65k | US$168m |
Compensation vs Market: Alexander's total compensation ($USD18.59M) is above average for companies of similar size in the US market ($USD13.50M).
Compensation vs Earnings: Insufficient data to compare Alexander's compensation with company performance.
CEO
Alexander Hardy (55 yo)
less than a year
Tenure
US$18,586,001
Compensation
Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023. He had been Chief Executive Officer at Genentech, Inc. since March 1, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$18.59m | no data | |
| CFO & Executive VP | 4.4yrs | US$4.85m | 0.038% $ 6.1m | |
| Executive VP & Chief Technical Officer | no data | US$5.70m | 0.015% $ 2.4m | |
| President of Worldwide Research & Development | 7.7yrs | US$9.66m | 0.058% $ 9.4m | |
| Group VP & Chief Accounting Officer | 2.1yrs | no data | 0.0011% $ 174.6k | |
| Chief Scientific Officer & Senior VP of Research and Early Development | no data | no data | no data | |
| Group Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 20.4yrs | US$5.19m | 0.030% $ 4.8m | |
| Senior VP & Chief Marketing Officer | 2.1yrs | no data | no data | |
| Executive VP & Chief People Officer | 5.4yrs | no data | no data | |
| Executive VP | 2.4yrs | no data | no data | |
| Senior Vice President of Technical Development | 2.7yrs | no data | no data |
2.7yrs
Average Tenure
53yo
Average Age
Experienced Management: BMRN's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$18.59m | no data | |
| Independent Chairman of the Board | 17.5yrs | US$515.44k | 0.060% $ 9.7m | |
| Independent Director | 8.4yrs | US$470.44k | 0.022% $ 3.5m | |
| Independent Director | less than a year | US$213.38k | no data | |
| Independent Director | 21.9yrs | US$486.44k | 0.049% $ 7.9m | |
| Independent Director | 7.9yrs | US$480.44k | 0.012% $ 2.0m | |
| Independent Director | 3.3yrs | US$473.94k | 0.0066% $ 1.1m | |
| Independent Director | 6.8yrs | US$486.94k | 0.014% $ 2.2m | |
| Independent Director | less than a year | US$213.38k | no data | |
| Independent Director | 4.9yrs | US$480.44k | 0.010% $ 1.6m | |
| Independent Director | less than a year | US$213.38k | no data |
4.9yrs
Average Tenure
64yo
Average Age
Experienced Board: BMRN's board of directors are considered experienced (4.9 years average tenure).